Core Viewpoint - The article emphasizes the importance of conducting personal in-depth research and due diligence before making investment decisions, highlighting the inherent risks involved in trading [3]. Group 1 - The analysis is intended solely for informational purposes and should not be interpreted as professional investment advice [3]. - There is a clear disclaimer regarding the lack of any stock, option, or derivative positions in the companies mentioned, indicating a neutral stance [2]. - The article expresses that past performance does not guarantee future results, underscoring the uncertainty in investment outcomes [4].

Viking Therapeutics TodayVKTXViking Therapeutics$22.98 -0.13 (-0.55%) 52-Week Range$18.92▼$81.86Price Target$89.75Add to WatchlistViking Therapeutics Inc. NASDAQ: VKTX has taken investors on a wild ride since the beginning of 2024. At one point, VKTX stock was up 375% from its closing price on January 2, 2024. But it’s been a steady move lower. As of the market close on April 15, 2025, the stock is within 10% of that January 2024 close. This week alone has been wild. Viking stock shot up approximately 12% ...

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.It has been roughly 3 months since my last Viking Therapeutics, Inc. (NASDAQ: VKTX ) article , where I discussed how VKTX had dropped 50% despite strong clinical progress in obesity and NASH due to broader concerns in theHe is the leader of the investing ...

No one ever claimed investing in the biotech industry was a smooth ride, but for shareholders of Viking Therapeutics (VKTX -2.18%), the turbulence has been extremely challenging thus far. The stock is down 71% over the past year, amid ongoing uncertainties regarding the timeline for future commercialization of its clinical pipeline and the broader stock market sell-off.Nevertheless, the company's prospects remain positive with its portfolio of therapeutic candidates covering metabolic and endocrine diseases ...

Viking Therapeutics, Inc. VKTX,  Eli Lilly And Co LLY and Novo Nordisk A/S NVO stocks are trading higher on Monday.Pfizer Inc. PFE announced on Monday that it will discontinue the development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist being investigated for chronic weight management.A single asymptomatic participant in one of the dose-optimization studies experienced potential drug-induced liver injury, which resolved after discontinuation of danuglipron.Also Read ...

Core Viewpoint - Viking Therapeutics has significant growth potential, but its stock has experienced volatility, losing over 40% of its value in 2023 after a 116% increase in 2022 [1][2]. Company Overview - Viking Therapeutics currently has a market capitalization of approximately $2.5 billion [2]. - The company is developing two promising drug candidates: VK2735, which has shown the ability to help patients lose around 15% of their body weight in a phase 2 trial, and VK2809, which has reduced liver fat by an average of 37% to 55% in a phase 2 trial for nonalcoholic fatty liver disease [2][3]. Market Potential - Both VK2735 and VK2809 have the potential to generate billions in revenue if they become blockbusters [4]. - The GLP-1 drug market is projected to be worth over $100 billion, with significant competition from major pharmaceutical companies [7]. Future Outlook - If VK2735 and VK2809 receive approval, Viking's valuation could potentially double or triple, but the company needs a more diversified drug portfolio to maximize its value [6][10]. - The timeline for revenue generation from these products could take multiple years, and the company incurred a net loss of $110 million in 2024, indicating ongoing financial challenges [9][10]. Investment Considerations - Despite the risks and uncertainties, Viking's current reduced valuation presents a potential investment opportunity due to its promising drug candidates [11]. - The company is viewed as an exciting stock to monitor, with the potential for significant long-term growth, although it may not be suitable for all investors [12].

Viking Therapeutics (VKTX -0.99%) is operating in one of the highest-growth pharma areas around. I'm talking about the weight loss drug market -- one that Morgan Stanley analysts say may multiply by 15 to surpass $100 billion later this decade. Viking doesn't sell weight loss drugs yet, but it could be on the way. The biotech is studying injectable and oral formulations of VK2735 in clinical trials, and results so far have been impressive. As for stock performance, Viking won there too in the early part of ...

Company Performance - Viking Therapeutics, Inc. closed at $23.91, reflecting a -0.99% change from the previous session, underperforming the S&P 500's daily gain of 0.38% [1] - The company's shares have decreased by 6.03% over the past month, compared to the Medical sector's loss of 3.56% and the S&P 500's loss of 5.59% [1] Earnings Forecast - The upcoming earnings disclosure is anticipated to show an EPS of -$0.34, indicating a 30.77% decline from the same quarter last year [2] Analyst Estimates - Recent adjustments to analyst estimates for Viking Therapeutics are crucial as they reflect changing business trends, with positive revisions indicating analyst optimism about the company's profitability [3] - The Zacks Rank system, which incorporates these estimate changes, suggests that estimate revisions correlate with near-term share price momentum [4] Zacks Rank - Viking Therapeutics currently holds a Zacks Rank of 3 (Hold), with no changes in the Zacks Consensus EPS estimate over the past month [5] - The Zacks Rank system has shown that 1 ranked stocks have yielded an average annual return of +25% since 1988 [5] Industry Overview - The Medical - Biomedical and Genetics industry, which includes Viking Therapeutics, has a Zacks Industry Rank of 66, placing it in the top 27% of over 250 industries [6] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]

Viking Therapeutics (VKTX) announced that it has completed enrolling study participants in the phase II VENTURE-Oral Dosing study, which is evaluating the safety and efficacy of the oral formulation of its experimental obesity drug VK2735. Data from this study is expected in the second half of 2025.This study has enrolled around 280 adults who are either obese or overweight and have at least one weight-related co-morbid condition. These patients have been evenly randomized to one of the six dosing arms of t ...

13-Week Study Evaluating the Safety and Efficacy of Oral VK2735 Dosed Once Daily Results Expected in 2H25 SAN DIEGO, March 26, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of VK2735, the company's dual agonist of the glucagon-like peptide 1 ...